Drugs / DSTP3086S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01283373 | Mar 2011 → Jan 2016 | prostate cancer | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSTP3086S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01283373 ↗ |
| Modality | Monoclonal antibody | “DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked to the potent antimitotic agent monomethyl auristatin E.” PMID 31689155 ↗ Nov 2019 |
| Route | Intravenous | “DSTP3086S administered intravenously” NCT01283373 ↗ |
| Target | STEAP1 | “DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked to the potent antimitotic agent monomethyl auristatin E.” PMID 31689155 ↗ Nov 2019 |